Rn. Miranda et al., STAGE IE NON-HODGKINS-LYMPHOMA INVOLVING THE DURA - A CLINICOPATHOLOGICAL STUDY OF 5 CASES, Archives of pathology and laboratory medicine, 120(3), 1996, pp. 254-260
Citations number
20
Categorie Soggetti
Pathology,"Medical Laboratory Technology","Medicine, Research & Experimental
Objective and Design.-Non-Hodgkin's lymphomas rarely present as a loca
lized mass involving the dura. In this report we describe the clinical
, histologic, and immunohistochemical features of five cases of stage
IF non-Hodgkin's lymphoma involving the dura. Patients.-Four women and
one man, 36 to 67 years of age (median, 50.6 years). Results.-Myelogr
aphy and magnetic resonance imaging scans revealed discrete expansile
masses involving the dura of the cervical, thoracic, and lumbar region
s of the spinal cord and the frontal lobe of the brain. Histologically
, the tumors were classified in the Working Formulation as small lymph
ocytic (2), diffuse large cell (2), and large cell immunoblastic (1) (
anaplastic large cell lymphoma). Four tumors were of B-cell lineage an
d the anaplastic large-cell lymphoma was of T-cell lineage. The two sm
all lymphocytic neoplasms had immunoglobulin heavy-chain gene rearrang
ements as shown by either Southern blot hybridization or the polymeras
e chain reaction. Four patients underwent decompression laminectomy; t
hree received spinal radiation; two received chemotherapy (one intrath
ecal, one systemic) for lymphocytosis of the cerebrospinal fluid. The
dural mass overlying the frontal lobe was excised and focally irradiat
ed. Clinical follow-up was available for all patients. Four patients w
ere alive 12 to 40 months after diagnosis and showed no evidence of re
current or disseminated disease. The patient with anaplastic large-cel
l lymphoma died 10 days after laminectomy, secondary to pulmonary thro
mboemboli. Conclusions.-We conclude that non-Hodgkin's lymphomas of va
ried histologic types and of either B- or T-cell lineage may rarely pr
esent as a stage IF dural mass. These lesions appear to have a good in
itial response to treatment; however, longer clinical follow-up is nec
essary to assess the incidence of relapse and final outcome.